Literature DB >> 9323725

Growth factors in age-related macular degeneration: pathogenic and therapeutic implications.

R N Frank1.   

Abstract

PURPOSE: To investigate the role of growth factors in choroidal neovascularization in humans with age-related macular degeneration (ARMD) and in rats with choroidal neovascularization produced by krypton laser photocoagulation.
METHODS: Autoradiography using 3H-thymidine in laser-treated rats. Light- and electron-microscopic immunocytochemistry using antibodies to several different growth factors and to the fibroblast growth factor (FGF) receptor. Tissues studied included the retinas of rats that had received krypton red laser photocoagulation, which induces formation of choroidal neovascularization 6-8 weeks after laser treatment, choroidal neovascular membranes (CNVMs) removed surgically from humans with ARMD and whole human eyes obtained postmortem with macular choroidal neovascular lesions from ARMD.
RESULTS: Nuclei of retinal pigment epithelium (RPE) and choriocapillary cells in laser-treated rats were labeled with 3H-thymidine up to 80 days after photocoagulation, maximally at 2-7 days after laser treatment. At all intervals, RPE cells in treated areas immunolabeled for aFGF and bFGF. Labeling was strongest within lysosomes. RPE cells in untreated regions did not immunolabel for growth factors. RPE cells from CNVMs in the maculas of humans with ARMD also immunolabeled for aFGF and bFGF. Some choriocapillary endothelial cells in human CNVMs became labeled in a regular array along their anteluminal and luminal plasma membranes with anti-bFGF antibodies and, in a similar pattern, with antibodies to the FGF receptor. Finally, serial sections from some CNVMs in ARMD patients were immunostained alternately for bFGF and for vascular endothelial growth factor (VEGF). RPE cells and choriocapillary endothelial cells in these membranes immunostained for VEGF. Many immunostained for both bFGF and VEGF. In whole human eyes with macular CNVMs RPE cells in regions of normal retina did not immunostain for these growth factors.
CONCLUSIONS: Several growth factors are not expressed at detectable levels by immunocytochemistry in normal RPE cells in rats or humans but do appear following photocoagulation or the development of CNVMs in ARMD. This suggests that these growth factors have a pathogenic role in choroidal neovascularization. Possibly, bFGF and VEGF act synergistically to accelerate neovascularization. The up-regulation of VEGF in CNVMs is of special interest because up-regulation of this growth factor in other systems appears to be stimulated by tissue hypoxia. Till now, hypoxia has not been considered a major pathogenic agent in the development of CNVMs in ARMD or other macular diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9323725     DOI: 10.1159/000268032

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  28 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

Review 2.  The many possible roles of stem cells in age-related macular degeneration.

Authors:  Sergio Caballero; Nilanjana Sengupta; Sven Crafoord; Raymond Lund; Friedrich E Kruse; Michael Young; Maria B Grant
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-18       Impact factor: 3.117

3.  The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization.

Authors:  Elizabeth Monaghan-Benson; John Hartmann; Aleksandr E Vendrov; Steve Budd; Grace Byfield; Augustus Parker; Faisal Ahmad; Wei Huang; Marschall Runge; Keith Burridge; Nageswara Madamanchi; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2010-08-27       Impact factor: 4.307

Review 4.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

5.  Expression profile of voltage-dependent Ca2+ channel subunits in the human retinal pigment epithelium.

Authors:  Sönke Wimmers; Linn Coeppicus; Rita Rosenthal; Olaf Strauss
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-02-13       Impact factor: 3.117

Review 6.  Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease.

Authors:  Joanna Kur; Eric A Newman; Tailoi Chan-Ling
Journal:  Prog Retin Eye Res       Date:  2012-05-03       Impact factor: 21.198

7.  Homozygosity for the +674C>T polymorphism on VEGF gene is associated with age-related macular degeneration in a Brazilian cohort.

Authors:  Luciana N Almeida; Rachel Melilo-Carolino; Carlos E Veloso; Patrícia A Pereira; Debora M Miranda; Luiz Armando De Marco; Marcio Bittar Nehemy
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

8.  Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat.

Authors:  W Y Shen; M J Yu; C J Barry; I J Constable; P E Rakoczy
Journal:  Br J Ophthalmol       Date:  1998-09       Impact factor: 4.638

9.  Inhibitory effects of verapamil isomers on the proliferation of choroidal endothelial cells.

Authors:  Stephan Hoffmann; Stephanie Balthasar; Ulrike Friedrichs; Marianne Ehren; Stephen J Ryan; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-09       Impact factor: 3.117

Review 10.  Role of growth factors and the wound healing response in age-related macular degeneration.

Authors:  Reinier O Schlingemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-18       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.